Global CFS Purchases Implant Sciences' QS-B220 for Air Cargo Screening Sale marks the latest in a series of U.S. air cargo sales to CCSFs, following TSA qualification
WILMINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today another TSA Certified Cargo Screening Facility (CCSF), Global CFS, has purchased its TSA-qualified QS-B220™ desktop explosives trace detector (ETD). CCSFs are certified by the TSA to screen air cargo packages for explosives before they are loaded onto airplanes.
Global CFS, Inc., located at Chicago's O'Hare International Airport, is a full service trucking company, providing Air and Ocean Freight delivery service of import and export cargo arriving at the Port of Chicago by air or railroad. As a bonded carrier, Global CFS services Illinois, Indiana, Iowa, Michigan, and Wisconsin. Global CFS is the home of U.S. Customs and Border Protection as Centralized Examination Station CES#1 for cargo inspections, and has Customs Inspectors on site. Global CFS's bonded warehouse/terminal cargo services include full accommodations for specialty freight needs, distribution, sorting, and segregation as an air freight and ocean freight break-bulk facility, operating 24/7-365 days a year. Global CFS, Inc. is a Certified Cargo Screening Facility with the Transportation Security Administration
"ETD is an important part of our ability to provide uncompromised security. Buying the QS-B220 gives us access to the most advanced technology while also reducing our maintenance and operation costs," stated Steve Panzarella Jr., President at Global CFS. "Additionally, the superior customer care and responsiveness of the Implant Sciences team has made them a joy to work with."
"The advantages of our QS-B220 make it a highly attractive alternative for facilities looking to replace previous generations of equipment, as our growing volume of sales demonstrates. We're very proud of our product's level of performance and the commitment to customer satisfaction that our entire sales and service team deliver. We look forward to the continued expansion of our presence in the market," commented Vice Sales and Marketing for Implant Sciences, Darryl Jones.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation